More Ups Than Downs In Latest Drug Price Adjustment
This article was originally published in PharmAsia News
Executive Summary
China's National Development and Reform Commission (NDRC) recently adjusted the price of 47 formulations for 26 types of generic drugs, including Mycetozoan and Rifampicin. While the previous 24 adjustments focused on lowering prices, the latest round raised the price of most drugs, up to six-fold. Analysts note that this adjustment will benefit industry development and protect the interests of local manufacturers producing cheap medicines with good quality. It could also indicate a new trend of drug price adjustment. However, others caution against relying on a single instance as a reflection of future policy. (Click here for more)